VNRX: Cost cutting being implemented in a plan to be cash flow neutral in 2025. Revenues from Nu.Q Vet Test Expected to Accelerate During 2H 2024
Volition's Nu.Q Vet Canine Cancer Screening Test are being launched in the U.S. and Europe by Antech on its Element I+ diagnostic point-of-sale...
141 Views
VolitionRx - Snaring sepsis, with early NETs detection
VolitionRx continues to make headway in growing a body of clinical evidence to build Nu.Q® NETs as a potential breakthrough tool in sepsis. These...
205 Views
VolitionRx - Vetting the pet health opportunity
While pets are increasingly being ‘humanized’, their healthcare has lagged advancements seen on the human side. With the COVID-19 pandemic...
105 Views
VolitionRx - Unravelling the web of NETs in sepsis
VolitionRx is a clinical diagnostics company with a different perspective on immunoassay technology for the detection and monitoring of severe...
669 Views
Video: VolitionRx - executive interview
VolitionRx is a multinational epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers...
399 Views